Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline <i>BRCA</i> or <i>PALB2</i> Mutations
Kim A. Reiss(University of Pennsylvania), Susan M. Domchek(University City Science Center), Heather Symecko(University of Pennsylvania), Shun Yu(University of Pennsylvania), Renae Judy(University of Pennsylvania), Katherine L. Nathanson(Translational Therapeutics (United States))
Cited by 61
Related Papers
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Network modeling links breast cancer susceptibility and centrosome dysfunction
|Nature Genetics|2007|634